We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

198 hedge funds and large institutions have $1.61B invested in Trevi Therapeutics in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 65 increasing their positions, 62 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $5.67M

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

8% more funds holding

Funds holding: 184 → 198 (+14)

3.45% more ownership

Funds ownership: 101.65% → 105.09% (+3.4%)

5% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 62

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

1% less capital invested

Capital invested by funds: $1.63B → $1.61B (-$17M)

Holders
198
Holders Change
+14
Holders Change %
+7.61%
% of All Funds
2.44%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
41
Increased
65
Reduced
62
Closed
24
Calls
$11.1M
Puts
$5.67M
Net Calls
+$5.44M
Net Calls Change
+$7.59M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$24.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$20M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.2M
4
Citadel Advisors
Citadel Advisors
Florida
+$11.7M
5
FCM
Frontier Capital Management
Massachusetts
+$9.92M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$14.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.5M
3
O
OrbiMed
New York
-$8.24M
4
Marshall Wace
Marshall Wace
United Kingdom
-$6.88M
5
EI
EAM Investors
California
-$6.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
51
Ensign Peak Advisors
Utah
$5.54M +$5.2M +464,746 New
UBS Group
52
UBS Group
Switzerland
$5.32M +$1.92M +171,564 +62%
KCA
53
KVP Capital Advisors
California
$4.94M – – –
JHC
54
Jones Hill Capital
New York
$4.42M +$4.14M +370,175 New
Invesco
55
Invesco
Georgia
$4.21M -$1.63M -145,942 -29%
OM
56
Opaleye Management
Massachusetts
$4.12M – – –
GC
57
GMT Capital
Georgia
$3.79M +$3.56M +317,700 New
SLAM
58
Swiss Life Asset Management
$3.66M +$240K +21,428 New
Bank of New York Mellon
59
Bank of New York Mellon
New York
$3.1M -$4.77K -426 -0.2%
SCM
60
Superstring Capital Management
New York
$3M +$1.16M +103,274 +70%
JGC
61
J. Goldman & Co
New York
$2.83M -$2.32M -207,398 -47%
FMI
62
F/M Investments
District of Columbia
$2.76M -$111K -9,881 -4%
Susquehanna International Group
63
Susquehanna International Group
Pennsylvania
$2.72M -$6.69M -597,860 -72%
PBM
64
Propel Bio Management
California
$2.65M +$2.51M +223,802 New
N
65
Nuveen
North Carolina
$2.25M +$54.3K +4,853 +3%
D.E. Shaw & Co
66
D.E. Shaw & Co
New York
$2.16M +$448K +40,032 +28%
Swiss National Bank
67
Swiss National Bank
Switzerland
$2.01M – – –
UBS AM
68
UBS AM
Illinois
$1.84M +$150K +13,435 +10%
State of Wisconsin Investment Board
69
State of Wisconsin Investment Board
Wisconsin
$1.61M +$159K +14,165 +12%
TCOT
70
Trust Company of Toledo
Ohio
$1.57M +$1.06M +95,000 +260%
Fifth Third Bancorp
71
Fifth Third Bancorp
Ohio
$1.53M +$1.44M +128,325 New
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$1.3M +$35.1K +3,139 +3%
Squarepoint
73
Squarepoint
New York
$1.24M +$1.16M +103,967 New
OC
74
Oppenheimer & Co
New York
$1.19M -$7.51K -671 -0.7%
LP
75
LMR Partners
United Kingdom
$1.19M – – –
1 2
3
4 5

TRVI Hedge Fund Activity: Q1 2026 in Review

198 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2026, worth a combined $1.61B — down 1% from $1.63B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new TRVI positions and 24 closed out — a net gain of 17 holders — while 65 added to existing stakes and 62 trimmed.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $24.3M. The largest seller was Octagon Capital Advisors, cutting an estimated $14.9M.

  • 198 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2026, up from 184 in Q4 2025.
  • Funds reported $1.61B of Trevi Therapeutics stock for Q1 2026, down 1% quarter-over-quarter.
  • 41 funds opened new Trevi Therapeutics positions in Q1 2026 and 24 closed out, a net change of +17 holders.
  • The largest Trevi Therapeutics buyer in Q1 2026 was Vestal Point Capital, an estimated $24.3M added.
  • The largest Trevi Therapeutics seller in Q1 2026 was Octagon Capital Advisors, an estimated $14.9M sold.

Based on aggregated 13F filings for Q1 2026.